US equities
|
SPCX
$167.43
▲+5.33%
NVDA
$236.42
▲+1.06%
MU
$1,064.70
▼-0.95%
TSLA
$378.32
▲+2.09%
MSFT
$525.80
▲+1.60%
SNDK
$1,708.33
▼-0.68%
INTC
$117.40
▼-1.62%
META
$744.66
▲+2.28%
SPCX
$167.43
▲+5.33%
NVDA
$236.42
▲+1.06%
MU
$1,064.70
▼-0.95%
TSLA
$378.32
▲+2.09%
MSFT
$525.80
▲+1.60%
SNDK
$1,708.33
▼-0.68%
INTC
$117.40
▼-1.62%
META
$744.66
▲+2.28%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
25.23
-0.39 (-1.54%)
Delayed Quote
Updated: 12:28 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Today 7:00 EDT
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
September 23, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 16, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion
↗
May 07, 2026
Via
Chartmill
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 03, 2026
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 03, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
September 02, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 01, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 01, 2026
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 18, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
↗
August 17, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations...
Via
MarketBeat
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
Phase III enrollment complete for zorevunersen with zero discontinuation rates.
Via
The Motley Fool
Topics
Earnings
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 05, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Q2 Earnings Call Highlights
↗
August 03, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
August 03, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
July 27, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
June 30, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 28, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 18, 2026
From
Stoke Therapeutics
Via
Business Wire
Stoke Therapeutics Q1 Earnings Call Highlights
↗
May 09, 2026
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 16, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 08, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 07, 2026
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
↗
March 27, 2026
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
March 26, 2026
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...
Via
MarketMinute
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
